ClinicalTrials.Veeva

Menu

Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

I

Institut Bergonié

Status and phase

Active, not recruiting
Phase 3

Conditions

Breast Cancer
Bladder Cancer
Lung Cancer
Lymphoma
Ovarian Cancer
Prostate Cancer
Colorectal Cancer

Treatments

Other: Geriatrician Intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT02704832
ID-RCB number 2015-A01417-42 (Other Identifier)
IB 2015-08

Details and patient eligibility

About

Randomized trials have already demonstrated that geriatric intervention was able to improve survival in the general elderly population but only a few have been performed in cancer patients. At the end, these data are not sufficient to consider geriatric intervention as validated in this setting. Case Management, coordinated by a geriatrician and a trained nurse, could improve prognosis of elderly patients with cancer. This approach, can be integrated in daily oncology practice. This strategy will be compared to usual oncological management in a randomized phase III trial.

Full description

Patients will first be screened using the G8 screening tool. If the resulting score is altered (G8 <= 14), patients will be included in the main study and randomized according to 2 modalities: Arm A / Usual care (treatment according to on-going regimens in oncology) or Arm B /Case management (assessment of the patient by the nurse and the geriatrician with interventions as prescribed by the geriatrician). The intervention will be considered effective if, at one year, compared to usual care there is a significant clinical improvement in overall survival (OS) without a significant deterioration or/and clinical improvement of at least one of the targeted quality of life (QoL) scores, without significant clinical deterioration in at least one of the targeted QoL scores and without significant difference in OS in favor of usual care.

If the resulting score is normal (G8 > 14), patients will be treated according to their physician-in-charge opinion. A minimal set of data will be collected (age, sex, tumor type, disease stage, performance status (PS), creatinine clearance, albumin and C-Reactive Protein (CRP) levels mainly) to allow for the characterization of the population in order to compare our results to those of other published series.

Enrollment

792 patients

Sex

All

Ages

70+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient older 70 years and older

  2. Performance status 0 to 3 (WHO)

  3. G8 and QLQ-C30 questionnaires 'score are available

  4. No previous geriatric evaluation during cancer treatment

  5. Locally advanced or metastatic disease :

    1. 1st line medical treatment :

      • Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
      • Colon and rectum : metastatic (unresectable metastasis),
      • Prostate cancer : metastatic and refractory to hormonal castration,
      • Bladder cancer : locally advanced or metastatic,
      • Ovarian cancer : advanced stage (IIb to IV),
      • Lung cancer : metastatic non-small cell,
      • Lymphomas (indolent and aggressive)
    2. Or 2nd line medical treatment :

      • Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
      • Colon and rectum : metastatic (unresectable metastasis),
      • Prostate cancer : metastatic and refractory to hormonal castration,
      • Ovarian cancer : advanced stage (IIb to IV),
      • Lymphomas (indolent and aggressive)
  6. Life expectancy over 6 months

  7. Signed informed consent

  8. Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).

Exclusion criteria

  1. Patient who already received 2 medical treatment lines

  2. Exclusive 1st or 2nd treatment lines of :

    • Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed),
    • Surgery,
    • Radiotherapy,
  3. "Best supportive care" treatment

  4. Patient unable to understand quality of life questionnaire

  5. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.

  6. Patient placed under guardianship

  7. Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE

  8. Previous enrolment in the present study

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

792 participants in 2 patient groups

Arm A
No Intervention group
Description:
Arm A "Standard oncological care": patients will be treated according to daily oncological practices as defined for each type of cancer, in the "Management protocol of Oncology" written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
Arm B
Experimental group
Description:
Arm B "Geriatrician Intervention": patients will be treated according to the same "Management protocol of Oncology" than patients in the arm "Standard oncological care". * Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the "Management protocol of Geriatrics". * The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months.
Treatment:
Other: Geriatrician Intervention

Trial contacts and locations

50

Loading...

Central trial contact

Caroline LALET; Pierre-Louis SOUBEYRAN, PU-PH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems